Literature DB >> 14527093

Absorption, distribution, metabolism and excretion of the cholecystokinin-1 antagonist dexloxiglumide in the rat.

C Webber1, C A Stokes, S Persiani, F Makovec, A McBurney, R P Kapil, B A John, T L Houchen, M D'Amato, L F Chasseaud.   

Abstract

Single oral doses of 14C-dexloxiglumide were rapidly and extensively absorbed in rats, and eliminated more slowly by females than by males. The respective half-lives were about 4.9 and 2.1 h. Following single intravenous doses, dexloxiglumide was characterised as a drug having a low clearance (6.01 and about 1.96 ml/min/kg in males and females respectively), a moderate volume of distribution (Vss, 0.98 and about 1.1 L/kg in males and females respectively) and a high systemic availability. It was extensively bound to plasma proteins (97%). Dexloxiglumide is mainly cleared by the liver. Its renal clearance was minor. In only the liver and gastrointestinal tract, were concentrations of 14C generally greater than those in plasma. Peak 14C concentrations generally occurred at 1-2 h in males and at 2-4 h in females. Tissue 14C concentrations then declined by severalfold during 24 h although still present in most tissues at 24 h but only in a few tissues (such as the liver and gastrointestinal tract) at 168 h. Decline of 14C was less rapid in the tissues of females than in those of males. Single intravenous or oral doses were mainly excreted in the faeces (87-92%), mostly during 24 h and more slowly from females than from males. Urines contained less than 11% dose. Mean recoveries during 7 days when 14C was not detectable in the carcass except in one female rat ranged between 93-101%. Biliary excretion of 14C was prominent (84-91% dose during 24 h) in the disposition of 14C which was also subjected to facile enterohepatic circulation (74% dose). Metabolite profiles in plasma and selected tissues differed. In the former, unchanged dexloxiglumide was the major component whereas in the latter, a polar component was dominant. Urine, bile and faeces contained several 14C-components amongst which unchanged dexloxiglumide was the most important (eg. up to 63% dose in bile). LC-MS/MS showed that dexloxiglumide was metabolised mainly by hydroxylation in the N-(3-methoxypropyl)pentyl sidechain and by O-demethylation followed by subsequent oxidation of the resulting alcohol to a carboxylic acid.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14527093     DOI: 10.1007/BF03190486

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  6 in total

Review 1.  Cholecystokinin antagonists.

Authors:  G N Woodruff; J Hughes
Journal:  Annu Rev Pharmacol Toxicol       Date:  1991       Impact factor: 13.820

Review 2.  Physiological parameters in laboratory animals and humans.

Authors:  B Davies; T Morris
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

3.  Regulation of rat hepatic cytochrome P-450: age-dependent expression, hormonal imprinting, and xenobiotic inducibility of sex-specific isoenzymes.

Authors:  D J Waxman; G A Dannan; F P Guengerich
Journal:  Biochemistry       Date:  1985-07-30       Impact factor: 3.162

4.  Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects.

Authors:  C Webber; A Roth; S Persiani; A J Peard; F Makovec; R P Kapil; B A John; J D Holding; M D'amato; Z R Cybulski; L F Chasseaud; L C Rovati
Journal:  Xenobiotica       Date:  2003-06       Impact factor: 1.908

5.  Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo.

Authors:  C Scarpignato; I Kisfalvi; M D'Amato; G Varga
Journal:  Aliment Pharmacol Ther       Date:  1996-06       Impact factor: 8.171

Review 6.  Role of cholecystokinin in the regulation of gastrointestinal motility.

Authors:  J R Grider
Journal:  J Nutr       Date:  1994-08       Impact factor: 4.798

  6 in total
  2 in total

Review 1.  Pharmacokinetic profile of dexloxiglumide.

Authors:  Stefano Persiani; Massimo D'Amato; Abhijeet Jakate; Partha Roy; Julie Wangsa; Ram Kapil; Lucio C Rovati
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  Absorption, distribution, metabolism and excretion of the cholecystokinin-1 antagonist dexloxiglumide in the dog.

Authors:  C Webber; C A Stokes; S Persiani; F Makovec; A McBurney; R P Kapil; B A John; M D'Amato; L F Chasseaud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Jan-Mar       Impact factor: 2.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.